|
|
Volumn 5, Issue 22, 2014, Pages 10963-10964
|
|
ADAM10 and ADAM17: New players in trastuzumab resistance
a
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
ADAM10 ENDOPEPTIDASE;
ADERBASIB;
ANTINEOPLASTIC AGENT;
EPIDERMAL GROWTH FACTOR RECEPTOR 2;
INCB 8765;
PROTEIN ADAM17;
TRASTUZUMAB;
TUMOR PROTEIN;
UNCLASSIFIED DRUG;
ADAM PROTEIN;
ADAM10 PROTEIN, HUMAN;
ERBB2 PROTEIN, HUMAN;
MEMBRANE PROTEIN;
MONOCLONAL ANTIBODY;
SECRETASE;
CANCER CELL LINE;
CANCER PROGNOSIS;
CANCER RESISTANCE;
EDITORIAL;
HUMAN;
NONHUMAN;
PROTEIN DOMAIN;
PROTEIN EXPRESSION;
RASH;
RECURRENCE FREE SURVIVAL;
TREATMENT RESPONSE;
UPREGULATION;
ANIMAL;
BREAST NEOPLASMS;
ENZYMOLOGY;
FEMALE;
METABOLISM;
ADAM PROTEINS;
AMYLOID PRECURSOR PROTEIN SECRETASES;
ANIMALS;
ANTIBODIES, MONOCLONAL, HUMANIZED;
ANTINEOPLASTIC AGENTS;
BREAST NEOPLASMS;
FEMALE;
HUMANS;
MEMBRANE PROTEINS;
RECEPTOR, ERBB-2;
TRASTUZUMAB;
|
|
EID: 84917706141
PISSN: None
EISSN: 19492553
Source Type: Journal
DOI: 10.18632/oncotarget.2794 Document Type: Editorial |
|
Times cited : (11)
|
|
References (8)
|
